Phaseline

Companies › BiomX

BiomX: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BX004
Combination of nebulized bacteriophages targeting Pseudomonas aeruginosa
PAERPhase 2Chronic Pseudomonas Aeruginosa Infection–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06998043BX004Phase 2Chronic Pseudomonas Aeruginosa InfectionInfectious diseaseMar 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PAER (1)

Companies with the same targets

–

Companies built like this

Osivax Artcline Shanghai HEP Pharmaceutical Curevo Green Cross

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.